Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 3:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 226 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Severe Asthma Clear all
Active, not recruiting Phase 4 Interventional

Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma

NCT05097287
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
75
States / cities
Cullman, Alabama • Sheffield, Alabama • Chandler, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 22, 2026, 3:57 AM EDT
Active, not recruiting Phase 3 Interventional

A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma

NCT05692180
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
6 Years to 18 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
11
States / cities
Torrance, California • Ocala, Florida • Owensboro, Kentucky + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 22, 2026, 3:57 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Expressions of TRPV1 in Airway of Asthmatics

NCT02952066
View directory record Official record
Conditions
Moderate Persistent Asthma, Severe Persistent Asthma, Nodule Solitary Pulmonary, Pulmonary Atelectasis
Interventions
Bronchial biopsy
Procedure
Lead sponsor
Lu Yuan Lee
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 22, 2026, 3:57 AM EDT
Completed Not applicable Interventional

Asthma and Obstructive Sleep Apnea (OSA)

NCT01026298
View directory record Official record
Conditions
Asthma, Obstructive Sleep Apnea
Interventions
FDA-Approved Treatment
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 73 Years
Enrollment
744 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Sep 22, 2026, 3:57 AM EDT
Completed Phase 3 Interventional

New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma

NCT00393952
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone propionate/Formoterol fumarate 250/10, Placebo, Fluticasone propionate/Formoterol fumarate 100/10, Fluticasone propionate 250, Formoterol fumarate 10
Drug
Lead sponsor
SkyePharma AG
Industry
Eligibility
12 Years and older
Enrollment
557 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
62
States / cities
Pell City, Alabama • Glendale, Arizona • Phoenix, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Sep 22, 2026, 3:57 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Airway Redox and Gender Determinants in Severe Asthma

NCT01759186
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
6 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2028
U.S. locations
4
States / cities
Cleveland, Ohio • Charlottesville, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 22, 2026, 3:57 AM EDT
Completed Phase 2 Interventional Results available

A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma

NCT01311661
View directory record Official record
Conditions
Asthma
Interventions
Placebo twice daily, Olodaterol low daily dose twice daily, Olodaterol medium daily dose twice daily, Olodaterol high daily dose once daily and placebo, Olodaterol medium daily dose once daily and placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 70 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
12
States / cities
Huntington Beach, California • Centennial, Colorado • Wheat Ridge, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2014 · Synced Sep 22, 2026, 3:57 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

UTMB Research on Severe Asthma (UROSA) Study

NCT02264691
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 65 Years
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Sep 22, 2026, 3:57 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma

NCT01634152
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Tiotropium low dose mcg, Tiotropium high dose
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
6 Years to 11 Years
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
10
States / cities
Rolling Hills Estates, California • Denver, Colorado • North Dartmouth, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Sep 22, 2026, 3:57 AM EDT
Completed No phase listed Observational

Severe Asthma Research Program - Wake Forest University

NCT01750411
View directory record Official record
Conditions
Asthma, Severe Persistent Asthma
Interventions
Not listed
Lead sponsor
Wake Forest University
Other
Eligibility
6 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
2
States / cities
Atlanta, Georgia • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 31, 2021 · Synced Sep 22, 2026, 3:57 AM EDT
Terminated Phase 2 Interventional

A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma

NCT06376045
View directory record Official record
Conditions
Asthma
Interventions
Rocatinlimab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
48
States / cities
Bakersfield, California • La Jolla, California • La Palma, California + 42 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 22, 2026, 3:57 AM EDT
Terminated Phase 3 Interventional Results available

Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma

NCT05398263
View directory record Official record
Conditions
Asthma
Interventions
Tezepelumab, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
9
States / cities
Newport Beach, California • Denver, Colorado • Newark, Delaware + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 22, 2026, 3:57 AM EDT
Completed Not applicable Interventional Results available

Phase I Assessment of Hypertonic Saline in Moderate to Severe Asthmatics

NCT03556683
View directory record Official record
Conditions
Moderate to Severe Asthma
Interventions
3% Hypertonic Saline, 7% Hypertonic Saline, Salbutamol
Device · Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Sep 22, 2026, 3:57 AM EDT
Completed Phase 2 Interventional

Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma

NCT06102005
View directory record Official record
Conditions
Asthma
Interventions
Lunsekimig, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
685 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
48
States / cities
Scottsdale, Arizona • Yuma, Arizona • Lancaster, California + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 22, 2026, 3:57 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation

NCT02869438
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
16
States / cities
Scottsboro, Alabama • Gilbert, Arizona • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2019 · Synced Sep 22, 2026, 3:57 AM EDT
Terminated Not applicable Interventional

BiPAP in Pediatric Moderate to Severe Asthma Randomized Control Trial

NCT05848115
View directory record Official record
Conditions
Asthma in Children
Interventions
Bi-level Positive Airway Pressure, Sham Bi-level Positive Airway Pressure
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
5 Years to 17 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Sep 22, 2026, 3:57 AM EDT
Recruiting Phase 2 Interventional

A Clinical Trial of Soluble Fiber for Asthma

NCT06372249
View directory record Official record
Conditions
Asthma in Children
Interventions
Inulin
Drug
Lead sponsor
Phoenix Children's Hospital
Other
Eligibility
6 Years to 17 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 22, 2026, 3:57 AM EDT
Completed No phase listed Observational Results available

Utilizing CT Based Imaging Parameters of Body Composition to Understand Heterogeneity of Response to Biologic Therapies in Severe Asthma Cohorts

NCT06922760
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 85 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Denver, Colorado • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Sep 22, 2026, 3:57 AM EDT
Completed Phase 4 Interventional Results available

Ideal Steroids for Asthma Treatment in the PICU

NCT03900624
View directory record Official record
Conditions
Asthma Childhood
Interventions
Dexamethasone
Drug
Lead sponsor
Johns Hopkins All Children's Hospital
Other
Eligibility
5 Years to 17 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Sep 22, 2026, 3:57 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications

NCT01576718
View directory record Official record
Conditions
Asthma
Interventions
Fp MDPI, Placebo MDPI, Flovent Diskus, albuterol/salbutamol
Drug · Other
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
889 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
148
States / cities
Birmingham, Alabama • Homewood, Alabama • Goodyear, Arizona + 114 more
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Sep 22, 2026, 3:57 AM EDT
Completed Phase 3 Interventional Results available

Study of Mepolizumab Safety Syringe in Asthmatics

NCT03021304
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
4
States / cities
Birmingham, Alabama • Los Angeles, California • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Sep 22, 2026, 3:57 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Clinical Study to Evaluate the Efficacy and Safety of VR506 Using a New Inhaler for the Treatment of Asthma

NCT01720069
View directory record Official record
Conditions
Asthma
Interventions
VR506
Drug
Lead sponsor
Vectura Limited
Industry
Eligibility
12 Years to 65 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
11
States / cities
Los Angeles, California • Denver, Colorado • Celebration, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Sep 22, 2026, 3:57 AM EDT
Terminated Phase 3 Interventional

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)

NCT05813288
View directory record Official record
Conditions
Eosinophilic Asthma, Asthma; Eosinophilic, Asthma
Interventions
Dexpramipexole Dihydrochloride, Placebo
Drug
Lead sponsor
Areteia Therapeutics
Industry
Eligibility
12 Years to 99 Years
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
76
States / cities
Mobile, Alabama • Chandler, Arizona • Peoria, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 22, 2026, 3:57 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma.

NCT03170271
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab (Medi-563), Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
100
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 87 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 22, 2026, 3:57 AM EDT